Meeting the needs of CML patients in resource-poor countries

• Published in: Hematology Vol. 2019; no. 1; pp. 433 - 442
• Main Authors: Malhotra, Hemant, Radich, Jerald, Garcia-Gonzalez, Pat
• Format: Journal Article
• Language: English
• Published: United States American Society of Hematology 06.12.2019
• Subjects: Adult; Developing Countries; Fusion Proteins, bcr-abl - antagonists & inhibitors; Hematopoietic Stem Cell Transplantation - economics; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - economics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy; Male; Patients, Borders, Money, and Mission: A Global of Chronic Myeloid Leukemia; Protein Kinase Inhibitors - economics; Protein Kinase Inhibitors - therapeutic use
• ISSN: 1520-4391; 1520-4383; 1520-4383
• DOI: 10.1182/hematology.2019000050

Subsequent to the development and global availability of BCR/ABL–targeted tyrosine kinase inhibitors (TKIs), the prognosis of patients with chronic myeloid leukemia (CML), at least those in the chronic phase, has markedly improved, and in the developed world, the average lifespan of these patients is now close to that of age- and sex-matched subjects without the disease. However, the situation in low- and middle-income countries (LMICs) may not be so rosy. Many important differences in hematological cancers, including CML, have been highlighted in various publications in LMICs vs developed countries. These include differences in incidence and prevalence rates, age and stage of disease at diagnosis, response rates, and survival. Some of the possible reasons proposed for these are varying socioeconomic milieu (impacting availability of effective drugs and essential monitoring), environmental factors (mainly exposure to viral infections and pesticides), nutritional factors with interplay of malnutrition and diet on drug absorption and blood levels, and possible unknown genetic factors. Although generic first-generation TKIs (imatinib) are available in many parts of the world, several challenges remain in providing optimal treatment to patients with CML in resource-poor countries. Some of these include availability of optimal and high-quality BCR/ABL testing, availability and expense related to use of second- and third-generation TKIs (nilotinib, dasatinib, bosutinib, and ponatinib) and hematopoietic stem cell transplantation, issues with compliance and toxicities of drugs, and ensuring a minimal standard-of-care treatment and monitoring for every patient diagnosed with CML. For the purpose of this article, the more objective country label—LMIC—coined by the World Bank will be used (gross national income per capita between $1026 and $3995; World Bank, June 2019). Some of these issues will be discussed in this article in greater detail by experts in the field in 3 different but interconnected sections.